AGEN

Agenus

6.03 USD
+0.15
2.55%
Updated Jul 30, 1:10 PM EDT
1 day
2.55%
5 days
-0.17%
1 month
31.95%
3 months
108.65%
6 months
70.34%
Year to date
95.15%
1 year
-0.50%
5 years
-90.22%
10 years
-96.34%
 

About: Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Employees: 316

0
Funds holding %
of 7,323 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

575% more call options, than puts

Call options by funds: $398K | Put options by funds: $59K

21% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 14

2% more funds holding

Funds holding: 85 [Q4 2024] → 87 (+2) [Q1 2025]

2.46% less ownership

Funds ownership: 35.97% [Q4 2024] → 33.51% (-2.46%) [Q1 2025]

12% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 25

45% less capital invested

Capital invested by funds: $23.1M [Q4 2024] → $12.8M (-$10.4M) [Q1 2025]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$6
0%
upside
Avg. target
$15.50
157%
upside
High target
$25
315%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Baird
Colleen Kusy
1%downside
$6
Neutral
Maintained
4 Jun 2025
HC Wainwright & Co.
Emily Bodnar
315%upside
$25
Buy
Upgraded
4 Jun 2025

Financial journalist opinion

Based on 5 articles about AGEN published over the past 30 days

Neutral
Business Wire
5 days ago
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that four abstracts highlighting clinical progress across its botensilimab and balstilimab immunotherapy programs have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place in Berlin, Germany from October 17-21. The highlight is an oral presentation that will feature emerging survival plateaus from a study of botensilimab plus balst.
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025
Positive
Zacks Investment Research
2 weeks ago
Agenus (AGEN) Surges 19.3%: Is This an Indication of Further Gains?
Agenus (AGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Agenus (AGEN) Surges 19.3%: Is This an Indication of Further Gains?
Positive
Zacks Investment Research
2 weeks ago
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
Here is how Agenus (AGEN) and CVS Health (CVS) have performed compared to their sector so far this year.
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
Positive
Zacks Investment Research
3 weeks ago
3 Top Earnings Acceleration Stocks to Buy for 2H25
Yext, Agenus and NCR Voyix show accelerating earnings growth, making them standout picks for the second half.
3 Top Earnings Acceleration Stocks to Buy for 2H25
Neutral
Business Wire
3 weeks ago
Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
LEXINGTON, Mass.--(BUSINESS WIRE)-- #CancerCare--Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (BOT/BAL) combination achieved a two-year survival rate of 42% along with a now more mature 21-month median overall survival (OS) in an expanded cohort of 123 patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases (NLM). Agenus also confirmed that it has reached agreement with the U.S. F.
Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
Positive
Zacks Investment Research
1 month ago
After Golden Cross, Agenus (AGEN)'s Technical Outlook is Bright
After reaching an important support level, Agenus Inc. (AGEN) could be a good stock pick from a technical perspective. AGEN recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
After Golden Cross, Agenus (AGEN)'s Technical Outlook is Bright
Neutral
Business Wire
1 month ago
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
LEXINGTON, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- #aiinbiotech--Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology.
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
Neutral
Business Wire
1 month ago
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
LEXINGTON, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a research collaboration to develop predictive biomarkers of response to Agenus' lead clinical stage immuno-oncology (IO) combination, botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1). The collaboration harnesses Noetik's proprietary virtual cell foundatio.
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
Neutral
Business Wire
1 month ago
Agenus Announces Virtual Annual Shareholders Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2025 and enter the 16-digit control number found in their proxy mat.
Agenus Announces Virtual Annual Shareholders Meeting
Positive
Benzinga
1 month ago
Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang
On Tuesday, Zydus Lifesciences Ltd. announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.'s AGEN U.S.-based biologics CMC facilities.
Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang
Charts implemented using Lightweight Charts™